NCT00718887 - Suboptimal Responders to Adefovir Switching to Entecavir | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2011

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Entecavir

Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks

DRUG

Adefovir/Entecavir

Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks

Trial Locations (8)

Local Institution, Beijing

Local Institution, Shenyang

Local Institution, Changchun

Local Institution, Shanghai

Local Institution, Nanjing

Local Institution, Nanchang

Local Institution, Guiyang

Local Institution, Shanghai